Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) – Research analysts at HC Wainwright issued their Q1 2023 EPS estimates for Allogene Therapeutics in a research report issued on Monday, November 21st. HC Wainwright analyst R. Burns expects that the company will earn ($0.70) per share for the quarter. HC Wainwright has a "Buy" rating and a $29.00 price objective on the stock. The consensus estimate for Allogene Therapeutics' current full-year earnings is ($2.38) per share. HC Wainwright also issued estimates for Allogene Therapeutics' Q2 2023 earnings at ($0.73) EPS, Q3 2023 earnings at ($0.76) EPS and Q4 2023 earnings at ($0.79) EPS.
Get Allogene Therapeutics alerts:ALLO has been the topic of a number of other reports. B. Riley reduced their price objective on shares of Allogene Therapeutics from $21.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, September 22nd. Raymond James cut shares of Allogene Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Wednesday, August 10th. Truist Financial reduced their price objective on shares of Allogene Therapeutics to $29.00 in a research note on Tuesday, August 23rd. Oppenheimer reduced their price objective on shares of Allogene Therapeutics to $32.00 in a research note on Thursday, October 13th. Finally, JMP Securities reiterated a "buy" rating and issued a $23.00 target price on shares of Allogene Therapeutics in a report on Tuesday, September 27th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Allogene Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $25.70.
Allogene Therapeutics Price Performance
ALLO opened at $10.70 on Tuesday. Allogene Therapeutics has a one year low of $6.43 and a one year high of $19.25. The company's 50 day simple moving average is $10.65 and its 200-day simple moving average is $11.43. The stock has a market capitalization of $1.54 billion, a P/E ratio of -4.86 and a beta of 0.59.Allogene Therapeutics (NASDAQ:ALLO – Get Rating) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.04. Allogene Therapeutics had a negative net margin of 126,580.16% and a negative return on equity of 37.74%. During the same quarter in the previous year, the business earned ($0.57) EPS.
Institutional Investors Weigh In On Allogene Therapeutics
Hedge funds have recently bought and sold shares of the company. Woodline Partners LP raised its holdings in shares of Allogene Therapeutics by 1,255.9% during the second quarter. Woodline Partners LP now owns 5,859,679 shares of the company's stock worth $66,800,000 after acquiring an additional 5,427,529 shares during the period. State Street Corp raised its holdings in shares of Allogene Therapeutics by 78.5% during the first quarter. State Street Corp now owns 7,877,648 shares of the company's stock worth $71,765,000 after acquiring an additional 3,464,603 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Allogene Therapeutics by 30.3% during the second quarter. Price T Rowe Associates Inc. MD now owns 5,559,176 shares of the company's stock worth $63,375,000 after acquiring an additional 1,292,441 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of Allogene Therapeutics by 62.5% during the first quarter. Goldman Sachs Group Inc. now owns 2,962,209 shares of the company's stock worth $26,986,000 after acquiring an additional 1,138,944 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in shares of Allogene Therapeutics during the first quarter worth $8,880,000. 84.81% of the stock is currently owned by institutional investors and hedge funds.
Allogene Therapeutics Company Profile
(Get Rating)
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.
Featured Articles
- Get a free copy of the StockNews.com research report on Allogene Therapeutics (ALLO)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- The Sell-Side Caps Gains In Dick's Sporting Goods
- Want to Get a 10% Dividend Yield, Look Here
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.